Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,456 as of Friday, Jan. 3, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,718 issues advancing vs. 1,181 declining with 172 unchanged. The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Herbalife ( HLF), down 5.3%, Illumina ( ILMN), down 2.3% and Regeneron Pharmaceuticals ( REGN), down 0.9%. Top gainers within the industry include Novo Nordisk A/S ( NVO), up 1.2%, Novartis ( NVS), up 0.6%, Sanofi ( SNY), up 0.5% and AstraZeneca ( AZN), up 0.5%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry lower today. As of noon trading, Teva Pharmaceutical Industries is down $0.27 (-0.7%) to $39.99 on light volume. Thus far, 876,631 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.5 million shares. The stock has ranged in price between $39.88-$40.38 after having opened the day at $40.27 as compared to the previous trading day's close of $40.26. Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.9 billion and is part of the health care sector. Shares are up 0.5% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 11 rate it a hold. TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and relatively poor performance when compared with the S&P 500 during the past year. Get the full Teva Pharmaceutical Industries Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.